Suppr超能文献

围手术期及侵入性操作中直接口服抗凝剂的管理

[Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].

作者信息

Llau J V, Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Torres L M

机构信息

Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario de Valencia, Universidad Católica «San Vicente Mártir», Valencia, España.

出版信息

Rev Esp Anestesiol Reanim. 2012 Jun-Jul;59(6):321-30. doi: 10.1016/j.redar.2012.01.007. Epub 2012 May 23.

Abstract

The new direct-acting oral anticoagulants (ACOD) in patients on prolonged treatment require the need to balance the risk of haemorrhage by administering them against the risk of thrombosis on withdrawing them. Recommendations for their management are proposed in the present article: A) Thromboprophylaxis and general anaesthesia: the performing of regional anaesthesia if administered with an ACOD as thromboprophylaxis requires some safety intervals based on their pharmacokinetic parameters; B) Management of ACOD in elective surgery: in patients with normal renal function and a low haemorrhage/thrombosis risk, stop the ACOD two days before the surgery; it the haemorrhage/thrombosis risk is high and/or renal function is impaired, therapy with a low molecular weight heparin is proposed from 5 days prior to the surgery, and C) Management of ACOD in urgent surgery and associated haemorrhage: the systematic prophylactic administration of haemostatics is recommended. In the event of acute bleeding that may place the life of the patient at risk (due to volume or location), the administration of concentrated prothrombin complex, fresh plasma, or factor VIIa, must be assessed, together with general control measures of acute haemorrhage. These recommendations should be considered in the context of the use drugs that do have a specific antidote, where their monitoring by the usual coagulation tests is not routine, and with those in which there is limited experience. We believe they need to be reviewed in the future, depending on further studies and clinical experience obtained.

摘要

对于长期接受治疗的患者,新型直接口服抗凝剂(ACOD)在给药时需要平衡出血风险,停药时则要平衡血栓形成风险。本文针对其管理提出了以下建议:A)血栓预防与全身麻醉:若将ACOD用于血栓预防,进行区域麻醉时需根据其药代动力学参数设定一些安全间隔时间;B)择期手术中ACOD的管理:对于肾功能正常且出血/血栓形成风险较低的患者,在手术前两天停用ACOD;若出血/血栓形成风险较高和/或肾功能受损,建议在手术前5天开始使用低分子量肝素进行治疗;C)急诊手术及相关出血时ACOD的管理:建议系统性预防性使用止血剂。若发生可能危及患者生命的急性出血(因出血量或出血部位),必须评估给予浓缩凝血酶原复合物、新鲜血浆或凝血因子VIIa,同时采取急性出血的一般控制措施。在使用没有特定解毒剂、常规凝血试验无法常规监测且经验有限的药物时,应考虑这些建议。我们认为,根据进一步的研究和临床经验,未来有必要对其进行重新审视。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验